A meta-analysis of 57 brain-imaging studies found that sleep disorders converge on structural changes in the thalamus — an attention and information-filtering hub — while parasomnias like sleepwalking carry a distinct signature in a region tied to motivation.
A five-year study of hemodialysis patients found that muscle wasting and depression form a hidden chain linking kidney failure to restless legs syndrome — suggesting screening should look beyond iron and cardiorenal numbers.
New research presented at the SLEEP 2026 annual meeting finds that shift workers with shift work sleep disorder carry two to three times the rates of hypertension, metabolic syndrome, and major cardiovascular events — a risk burden that persists even after controlling for lifestyle factors.
A 10-year study tracking 777 older adults with obstructive sleep apnea found that those who used CPAP showed significantly slower cognitive decline than those who did not — suggesting the breathing device may protect brain function during aging.
A JAMA Network Open systematic review warns that melatonin is the leading cause of unsupervised medication exposure in young children, with a 530% rise in pediatric ingestions over a decade — yet long-term safety data remain largely absent.
A $14 million federally funded clinical trial will compare CPAP, mandibular advancement devices, and a pharmacological combination head-to-head in 2,400 patients — the largest comparative effectiveness study ever conducted for obstructive sleep apnea.
A randomized trial presented at SLEEP 2026 found that reishi mushroom extract reduced insomnia severity scores by 8.7 points over 8 weeks, compared with 5.6 points for melatonin — a statistically significant difference that challenges assumptions about natural sleep aids.